Jade Biosciences, Inc. JBIO 深 沪
已收盘 02-06 16:00:00 美东时间
15.32
+0.930
+6.46%
华盛通- 最 高15.99
- 今 开14.82
- 成交量 23.08万股
- 最 低 14.54
- 昨 收 14.39
- 总市值 7.55亿
- 52周最高 17.71
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 -5.60
- 委 比 90.04%
- 总股本 4931.43万
- 历史最高 1050.525
- 量 比 0.80
- 振 幅 10.08%
- 历史最低 -40.25
- 每 手 1
- 风险率 3.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) fell sharply during Frid...
01-03 01:23
Jade Biosciences Raises $45M in Private Stock Offering Of 3.21M Shares At $14/Share To Advance Autoimmune Drug Research
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a
2025-12-15 20:08
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $17
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and raises the price target from $14 to $17.
2025-11-18 22:12
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
2025-11-18 00:39
Jade Biosciences Q3 EPS $(0.48) Beats $(0.66) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.66) by 27.27 percent.
2025-11-14 05:33
Jade Biosciences To Present New Preclinical Safety, Translational Data For Immunoglobulin A Nephropathy Candidate JADE101 American Society of Nephrology Kidney Week
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing
2025-10-18 04:09
